Health Prob Civil. 2021; 15(4): 255-269
1. Korzeniewski K. [Viral haemorrhagic fevers]. Forum Medycyny Rodzinnej. 2012; 6(5): 205-221 (in Polish).
2.
Korzeniewski K. [Viral hemorrhagic fevers – selected clinical problems]. Gdynia: Via Medica; 2012 (in Polish).
3.
Zieliński A, Rosińska M, Gut W. [Hemorrhagic fevers – epidemiology and clinics]. Przegląd Epidemiologiczny. 2003; 57: 639-54 (in Polish).
4.
www.cdc.gov/ncidod/diseases [Internet]. Atlanta: Centers for Disease Control and Prevention. National Center for Infectious Diseases, Special Pathogens Branch [cited 2017 Dec 12]. Available from: www.cdc.gov/ ncidod/diseases
5.
LeDuc JW. Epidemiology of hemorrhagic fever viruses. Rev Infect Dis. 1989; 11(Suppl 4): 730-735. https://doi.org/10.1093/clinids/11.Supplement_4.S730
6.
McCormack J, Sorrell T, Johnson P, Yung A, Spelman D, Street A. Infectious diseases: a clinical approach. Melbourne: IP Communications; 2014.
7.
Moreno ES, Agostini I, Holzmann I, Di Bitetti MS, Oklander LI, Kowalewski MM, et al. Yellow fever impact on brown howler monkeys (Alouatta guariba clamitans) in Argentina: a metamodelling approach based on population viability analysis and epidemiological dynamics. Mem. Inst. Oswaldo Cruz. 2015; 110: 865-876. https://doi.org/10.1590/0074-02760150075
8.
Fernandes NC, Cunha MS, Guerra JM, Réssio RA, Cirqueira CdS, Iglezias SDA, et al. Outbreak of yellow fever among Nonhuman primates. Espirito Santo, Brazil, 2017. Emerg. Infect. Dis. 2017; 23: 2038-2041. https://doi.org/10.3201/eid2312.170685
9.
Auguste AJ, Lemey P, Bergren NA, Giambalvo D, Moncada M, Morón D, et al. Enzootic transmission of yellow fever virus, Venezuela. Emerg. Infect. Dis. 2015; 21: 99-102. https://doi.org/10.3201/eid2101.140814
10.
Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Hemorrhagic fever viruses as biological weapons. Medical and public health menagement (consensus statement). JAMA. 2002; 287(18): 2391-404. https://doi.org/10.1001/jama.287.18.2391
11.
Wilder-Smith A. Viral hemorrhagic fevers. In: Schwartz E., editor. Tropical diseases in travelers. Oxford: Wiley-Blackwell; 2009. 243-253.
12.
Wu W, Ren H, Lu L. Increasingly expanded future risk of dengue fever in the Pearl River Delta, China. PLoS Negl Trop Dis. 2021; 15(9): e0009745. https://doi.org/10.1371/journal.pntd.0009745
13.
Hussain-Alkhateeb L, Rivera Ramírez T, Kroeger A, Gozzer E, Runge-Ranzinger S. Early warning systems (EWSs) for chikungunya, dengue, malaria, yellow fever, and Zika outbreaks: what is the evidence? A scoping review. PLoS Negl Trop Dis. 2021; 15(9): e0009686. https://doi.org/10.1371/journal.pntd.0009686
14.
Nimmannitya S. Dengue and dengue hemorrhagic fever. In: Cook GC, Zumla AI., editors. Manson’s tropical diseases. 22nd edition. London: Saunders Elsevier; 2009. p. 753-760. https://doi.org/10.1016/B978-1-4160- 4470-3.50045-8
15.
Halstead SB, Lan N, Myint T, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. EID. 2002; 8(12): 1474-1479. https://doi.org/10.3201/eid0812.020170
16.
Wang WK, Chao DY, Kao CL, Han-Chung W, Yung-Ching L, Chien-Ming L, et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology. 2003; 305(2): 330-88. https://doi.org/10.1006/viro.2002.1704
17.
Yeh TM, Liu H, Lin YS, Yee-Shin Lin, Shun-Hua C, Ching-Chuan L, et al. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001; 8(5): 377-388. https://doi.org/10.1007/BF02255946
18.
Mairuhu AT, Mac Gillavry MR, Setiati TE, Soemantri A, H ten C, Brandjes DPM, et al. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis. 2003; 3(1): 33-41. https://doi.org/10.1016/S1473-3099(03)00487-0
19.
Chiou-Feng L, Huan-Yao L, Ai-Li S, Ching-Chuan L, Hsiao-Sheng L, Trai-Ming Y, et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med. Virol. 2003; 69(1): 82-90. https://doi.org/10.1002/jmv.10261
20.
Clark MB, Schaefer TJ. West Nile virus. Treasure Island (FL): StatPearls Publishing; 2021.
21.
Nelson KE. Emerging vector-borne infections. In: Nelson KE, Williams CM., editors. Infectious disease epidemiology: theory and practice. 2nd edition. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2007. p. 1023-1057.
22.
Karan LS, Ciccozzi M, Yakimenko VV, Lo Presti A, Cella E, Zehender G, et al. The deduced evolution history of Omsk hemorrhagic fever virus. J Med Virol. 2014; 86(7): 1181-1187. https://doi.org/10.1002/jmv.23856
23.
Morse LJ. Modes of transmission of hemorrhagic fevers. JAMA. 2002; 288: 571. 24. Gupta N, Wilson W, Neumayr A, Saravu K. Kyasanur forest disease: state-of-the-art review. QJM. 2020; Nov 16: hcaa310. https://doi.org/10.1093/qjmed/hcaa310
24.
Solomon T, Mallewa MJ. Dengue and other emerging flaviviruses. J. Infect. 2001; 42: 104-115. https://doi.org/10.1053/jinf.2001.0802
25.
Parvi K. Clinical, clinicopathologic and hematologic features of Kyasanur forest disease. Rev Infect Dis. 1989; 11(Suppl. 4): S854-9. https://doi.org/10.1093/clinids/11.Supplement_4.S854
26.
Fanelli A, Buonavoglia D. Risk of Crimean Congo haemorrhagic fever virus (CCHFV) introduction and spread in CCHF-free countries in southern and Western Europe: a semi-quantitative risk assessment. One Health. 2021; 13: 100290. https://doi.org/10.1016/j.onehlt.2021.100290
27.
Jonkmans N, D’Acremont V, Flahault A. Scoping future outbreaks: a scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases. BMJ Glob Health. 2021; 6(9): e006623. https://doi.org/10.1136/bmjgh-2021-006623
28.
Jaureguiberry S, Tattevin P, Tarantola A, Legay F, Tall A, Nabeth P, et al. Imported Crimean-Congo hemorrhagic fever. J. Clin. Microbiol. 2005; 43: 4905-4907. https://doi.org/10.1128/JCM.43.9.4905-4907.2005
29.
Khan AS, Maupin GO, Rollin PE, Noor AM, Shurie HHM, Shalabi AGA, et al. An outbreak of CrimeanCongo hemorrhagic fever in the United Arab Emirates. Am J Trop Med. Hyg. 1997; 57: 519-25. https://doi.org/10.4269/ajtmh.1997.57.519
30.
Watts DM, Flick R, Peters CJ, Shope RE. Bunyaviral fevers: Rift valley fever and Crimean-Congo hemorrhagic fever. In: Guerrant RL, Walker DH, Weller PF., editors. Tropical infectious diseases, principles, pathogens & practice. 2nd edition. Philadelphia: Churchill Livingdtone Elsevier; 2006. p. 756-760. https://doi.org/10.1016/ B978-0-443-06668-9.50072-7
31.
Kuthyar S, Anthony CL, Fashina T, Yeh S, Shantha JG. World Health Organization high priority pathogens: ophthalmic disease findings and vision health perspectives. Pathogens. 2021; 10(4): 442. https://doi.org/10.3390/pathogens10040442
32.
Mostafavi E, Ghasemian A, Abdinasir A, Nematollahi Mahani SA, Rawaf S, Salehi Vaziri M, et al. Emerging and re-emerging infectious diseases in the WHO Eastern Mediterranean region, 2001-2018. Int J Health Policy Manag. Epub 2021 Mar 6. https://doi.org/10.34172/ijhpm.2021.13
33.
Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis. 2001; 33: 1707-1712. https://doi.org/10.1086/322620
34.
Peters JC, Mills JN, Spiropoulou C, Zaki SR, Rollin PE. Hantavirus infections. In: Guerrant RL, Walker DH, Weller PF., editors. Tropical infectious diseases. Principles, pathogens & practice. 2nd edition. Philadelphia: Churchill Livingstone Elsevier; 2006. p. 762-776. https://doi.org/10.1016/B978-0-443-06668-9.50073-9
35.
Schmaijohn C, Hjelle B. Hantavirus: aglobal disease problem. EID. 1997; 3(2): 95-104. https://doi.org/10.3201/ eid0302.970202
36.
Peters CJ, Simson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999; 50: 531-545. https://doi.org/10.1146/annurev. med.50.1.531
37.
Raftery MJ, Kraus AA, Ulrich R, Krüger DH, Schönrich G. Hantavirus infection of dendritic cells. J Virol. 2002; 76(21): 10724-10733. https://doi.org/10.1128/JVI.76.21.10724-10733.2002
38.
Geimonen E, Neff S, Raymond T, Kocer SC, Gavrilovskaya IN, Mackow ER, et al. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell resposes. Proc. Natl Acad Sci USA. 2002; 99(21): 13837- 13842. https://doi.org/10.1073/pnas.192298899
39.
Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. Pathogenic hantaviruses selectively inhibit β3 integrin directed endothelial cell migration. Arch Virol. 2002; 147(10): 1913-1931. https://doi.org/10.1007/ s00705-002-0852-0
40.
Mandell GL, Bennett SE, Dolin R. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Virus Res. 2011; 162: 138-147.
41.
Macneil A, Nichol ST, Spiropoulou CF. Hantavirus pulmonary syndrome. Virus Res. 2011; 162: 138-147. https://doi.org/10.1016/j.virusres.2011.09.017
42.
Korzeniewski K. [Medicine in travel]. Warszawa: e-PAGINA; 2012. p. 119-139 (in Polish).
43.
Pittalis S, Fusco FM, Lanini S, Nisii C, Puro V, Lauria FN, et al. Case definition for Ebola and Marburg haemorrhagic fevers: a compelx challange for epidemiologists and clinicians. New Microbiol. 2009; 32: 359- 367.
44.
Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011; 377: 849-862. https://doi.org/10.1016/ S0140-6736(10)60667-8
45.
Macneil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases?. PLoS Negl. Trop. Dis. 2012; 6: e1546. https://doi.org/10.1371/journal.pntd.0001546
46.
Iwamura T, Guzman-Holst A, Murray KA. Accelerating invasion potential of disease vector Aedes aegypti under climate change. Nat Commun. 2020; 11: 2130. https://doi.org/10.1038/s41467-020-16010-4
Copyright: © 2021 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
